Peptide Calculator: How Much to Draw for a Prescribed Dose
- Calculator
- About 3 min
- Dimensional analysis (Boyer 2016), U-100 syringe convention
- Runs in your browser, nothing is sent
- Medical review: Medical review pending
What this calculator works out
The vial states a weight, the prescription states a weight, and the syringe is marked in volume. Everything here is the bridge between them for one dose from one vial. The diluent volume is taken as given on this page; if you are still deciding it, the reconstitution page is the one to open.
-
mL
The volume for this dose
-
units
The mark to draw to
-
doses
What the vial still covers
How this compares with a typical online quiz
| Feature | Typical free quiz | Regenerated.com |
|---|---|---|
| Answers the draw question in one screen | Sometimes | Yes; volume, syringe mark, concentration and doses left |
| Suggests or defaults a dose | Often | Never; the dose comes from your prescription |
| Checks the volume against the syringe you own | No | Yes, 0.3, 0.5 and 1 mL U-100 sizes |
| Shows the arithmetic and names its source | Rarely | Dimensional analysis, Boyer 2016, printed with the result |
| Sells or links to peptides | Often | Never; no products, no sourcing |
| Answers sent to a server | Often | Never; scored in your browser, counts-only events |
Reading a U-100 insulin syringe
Insulin syringes are marked in units, not milliliters, because they were designed for U-100 insulin, which holds 100 units in every milliliter. The scale is therefore a volume scale in disguise: 100 units is 1.0 mL, 50 units is 0.5 mL, 10 units is 0.1 mL and a single unit is 0.01 mL. The calculator uses exactly that convention, and the units it prints are only correct on a U-100 syringe. A U-40 syringe, sold for some veterinary insulins, has a different scale and would deliver two and a half times the intended volume if the U-100 number were used.
Syringes come in 0.3 mL (30 units, marked in half units or single units), 0.5 mL (50 units) and 1 mL (100 units) sizes. The smaller the syringe, the wider the spacing between marks and the easier it is to draw a small volume accurately. If your result lands under about 5 units, a more dilute vial (more water, same peptide) moves the same dose to a larger, easier-to-read volume; that is a question for the prescriber or pharmacist, not something to change on your own.
Why the number you draw is not always the number that goes in
A syringe measures better than it delivers. The hub of a U-100 syringe holds a small volume of liquid that never leaves it, in the region of 0.02 to 0.07 mL depending on the needle and hub, and that liquid was part of what you drew but is not part of what was injected. At insulin-sized volumes clinicians handle this by using the same syringe type every time rather than by adjusting the number. Air matters more than dead space: a bubble the size of a unit is a unit of dose that did not go in, so tap the barrel and clear the air before reading, and read the mark at eye level rather than from above.
Rounding is the other place the number moves. The result prints one decimal of a unit because the direction of the rounding matters, not because a barrel can be read that finely. Draw to the nearest line your syringe actually has, usually a whole unit on a 1 mL barrel and often a half unit on a 0.3 mL one. If the dose asks for a precision your syringe does not offer, that is a question for the prescriber or the dispensing pharmacist about the concentration, not a reason to judge the space between two lines. And when a pharmacy label states a concentration, check it against the number here on every new vial: if the two disagree, the volume that went into the vial is not the volume you entered.
Regulatory status of compounded peptides
Peptides prescribed in US clinics fall into three regulatory groups. A few are FDA-approved drugs for a specific indication, such as tesamorelin for HIV-associated lipodystrophy and bremelanotide for hypoactive sexual desire disorder in premenopausal women; use outside those indications is clinician-directed off-label prescribing. Many others have never been approved for any indication, and whether a pharmacy may compound them at all turns on the FDA's bulk drug substance lists: section 503A lets a pharmacy compound from a bulk substance only if that substance has a USP or NF monograph, is a component of an FDA-approved drug product, or appears on the 503A bulks list. BPC-157 is the clearest case. The FDA placed it in 503A category 2 for significant safety risks in September 2023, alongside a group of other peptides. Its 503A category list updated April 22, 2026 removed twelve of those peptides, BPC-157 among them, from category 2 because the nominations were withdrawn by the nominators, and its safety-risk page, current as of April 22, 2026, lists them among the withdrawn nominations with the safety concerns still set out. We checked both on October 8, 2026. A withdrawn nomination is a decision by whoever nominated the substance, not an FDA finding that the substance is safe, and it did not put any of those peptides on the 503A bulks list, so a US pharmacy still has no route under 503A to compound them from bulk. The FDA consulted its Pharmacy Compounding Advisory Committee on July 23 and 24, 2026 about adding seven of them, having proposed in its own briefing document that none be included; that advice is non-binding and the agency had not acted on it as of October 8, 2026. The lists change, so the FDA's own pages and the content-current-as-of date each one carries are the authority.
None of this changes the arithmetic on this page, but it matters for what you ask a clinic: which pharmacy fills the prescription, what the label states, and whether the clinician explains the evidence and the regulatory status before prescribing. The clinic guide linked in the steps below covers those questions in more depth.
Methodology and sources
The calculator applies the dimensional analysis taught in pharmacy and nursing dosage-calculation texts, as set out in Boyer's Math for Nurses (9th edition, 2016), to one vial that has already been reconstituted. It answers the last question in the chain: given this vial, this diluent volume and this prescription, how much liquid do you draw. Choosing the diluent volume is a different question, worked on the peptide reconstitution calculator, and reading a prescription written in micrograms into syringe units is a third, worked dose-first on the peptide dosage calculator. No clinical judgment enters any step here, which is why the engine prints a fixed line above the inputs and the result saying that this is arithmetic for a dose your clinician prescribed and not a recommendation.
Concentration in mcg/mL equals vial milligrams times 1,000 divided by diluent milliliters. Volume per dose in milliliters equals the dose in micrograms divided by that concentration. Units on a U-100 insulin syringe equal milliliters times 100, because a U-100 syringe holds 100 units per milliliter. Doses per vial equals the vial's micrograms divided by the dose, rounded down. Worked example: a 5 mg vial reconstituted with 2 mL holds 5,000 / 2 = 2,500 mcg/mL. A 250 mcg dose is 250 / 2,500 = 0.1 mL, which is 10 units, and the vial holds 5,000 / 250 = 20 doses.
The limits are the limits of the inputs. The arithmetic assumes the vial label is accurate, that the full diluent volume went into the vial and dissolved the powder completely, and that the syringe is U-100. It does not account for the small dead space in a syringe hub, for peptide lost on the vial wall, or for a vial that has passed its beyond-use date. Results are rounded to one decimal of a unit; a syringe cannot be read that finely, so round to the nearest half unit or unit your syringe is marked in.
Medical review: Medical review pending. Last updated .
References
- Boyer MJ. Math for Nurses: A Pocket Guide to Dosage Calculation and Drug Preparation. 9th ed. Philadelphia, PA: Wolters Kluwer; 2016.
- United States Pharmacopeia. General Chapter 797: Pharmaceutical Compounding, Sterile Preparations. Rockville, MD: USP; revised 2023. https://www.usp.org/compounding/general-chapter-797
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of April 22, 2026; checked October 8, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Institute for Safe Medication Practices. ISMP Guidelines for Optimizing Safe Subcutaneous Insulin Use in Adults. Horsham, PA: ISMP; 2017. https://www.ismp.org/guidelines/subcutaneous-insulin
- US Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act, category list updated May 14, 2026 (and the April 22, 2026 version recording the withdrawn nominations), with the FDA briefing document for the Pharmacy Compounding Advisory Committee meeting of July 23 and 24, 2026. Checked October 8, 2026. https://www.fda.gov/media/94155/download and https://www.fda.gov/media/193342/download